{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:51Z","timestamp":1792787811620,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Postgraduate Innovation Research Project Fund of Harbin Medical University","award":["YJSCX2020-29HYD"],"award-info":[{"award-number":["YJSCX2020-29HYD"]}],"id":[{"id":"https:\/\/ror.org\/05jscf583","id-type":"ROR","asserted-by":"crossref"}]},{"name":"China Academy of Management Research Institute, Institute of Education Science, Key Research Project of Scientific and Educational Innovation","award":["KJCX209-2"],"award-info":[{"award-number":["KJCX209-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-06204-x","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:29:54Z","timestamp":1783006194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical observation of renal artery stenosis treated with PCSK9 inhibitor"],"prefix":"10.1186","volume":"26","author":[{"given":"Fali","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"6204_CR1","doi-asserted-by":"crossref","unstructured":"Silva J, Tonheiro J, Rodrigues F. The Silent Enemy Called Renal Artery Stenosis: A Mini-Review. 2025, 4(1):10.","DOI":"10.3390\/jvd4010010"},{"issue":"3","key":"6204_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1055\/s-0041-1730004","volume":"9","author":"T Gunawardena","year":"2021","unstructured":"Gunawardena T. Atherosclerotic Renal Artery Stenosis: A Review. Aorta (Stamford Conn). 2021;9(3):95\u20139.","journal-title":"Aorta (Stamford Conn)"},{"issue":"5","key":"6204_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.mcna.2023.04.004","volume":"107","author":"AM Morrison","year":"2023","unstructured":"Morrison AM, Sullivan AE, Aday AW. Atherosclerotic Disease: Pathogenesis and Approaches to Management. Med Clin N Am. 2023;107(5):793\u2013805.","journal-title":"Med Clin N Am"},{"issue":"6","key":"6204_CR4","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1161\/HYPERTENSIONAHA.119.13393","volume":"74","author":"PY Courand","year":"2019","unstructured":"Courand PY, Dinic M, Lorthioir A, Bobrie G, Grataloup C, Denari\u00e9 N, Soulat G, Mousseaux E, Sapoval M, Azizi M, et al. Resistant Hypertension and Atherosclerotic Renal Artery Stenosis: Effects of Angioplasty on Ambulatory Blood Pressure. A Retrospective Uncontrolled Single-Center Study. Hypertens (Dallas Tex: 1979). 2019;74(6):1516\u201323.","journal-title":"Hypertens (Dallas Tex: 1979)"},{"key":"6204_CR5","doi-asserted-by":"publisher","first-page":"e939881","DOI":"10.12659\/AJCR.939881","volume":"24","author":"J Alex","year":"2023","unstructured":"Alex J, Rajpurohit D, Zughaib M. Renovascular Hypertension with Progressive Atherosclerotic Renal Artery Stenosis in an Elderly Patient with Known Fibromuscular Dysplasia: A Case Report. Am J case Rep. 2023;24:e939881.","journal-title":"Am J case Rep"},{"issue":"2","key":"6204_CR6","first-page":"213","volume":"58","author":"D Perkov","year":"2019","unstructured":"Perkov D, Premu\u017ei\u0107 V, Smiljani\u0107 R, Fodor L, Dobrota S, Jelakovi\u0107 B. OSTIAL VERSUS TRUNCAL RENAL ARTERY STENOSIS: PREDICTOR OF LARGE ARTERY ATHEROSCLEROSIS SEVERITY AND HIGHER MORTALITY. Acta Clin Croatica. 2019;58(2):213\u201320.","journal-title":"Acta Clin Croatica"},{"issue":"3","key":"6204_CR7","doi-asserted-by":"publisher","first-page":"e58635","DOI":"10.1371\/journal.pone.0058635","volume":"8","author":"TA Macedo","year":"2013","unstructured":"Macedo TA, Pedrosa RP, Costa-Hong V, Kajita LJ, Morais GR, De Lima JJ, Drager LF, Bortolotto LA. Renal artery stenosis predicts coronary artery disease in patients with hypertension. PLoS ONE. 2013;8(3):e58635.","journal-title":"PLoS ONE"},{"issue":"5","key":"6204_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/0003319712451900","volume":"64","author":"H Yorgun","year":"2013","unstructured":"Yorgun H, Kabak\u00e7\u0131 G, Canpolat U, Aytemir K, Fatiho\u011flu G, Karakulak UN, Kaya EB, \u015eahiner L, Tokg\u00f6zo\u011flu L, Oto A. Frequency and predictors of renal artery stenosis in hypertensive patients undergoing coronary angiography. Angiology. 2013;64(5):385\u201390.","journal-title":"Angiology"},{"issue":"4","key":"6204_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jus.2009.09.006","volume":"12","author":"A Granata","year":"2009","unstructured":"Granata A, Fiorini F, Andrulli S, Logias F, Gallieni M, Romano G, Sicurezza E, Fiore CE. Doppler ultrasound and renal artery stenosis: An overview. J Ultrasound. 2009;12(4):133\u201343.","journal-title":"J Ultrasound"},{"key":"6204_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/5584_2016_170","volume":"956","author":"M Boddi","year":"2017","unstructured":"Boddi M. Renal Ultrasound (and Doppler Sonography) in Hypertension: An Update. Adv Exp Med Biol. 2017;956:191\u2013208.","journal-title":"Adv Exp Med Biol"},{"key":"6204_CR11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"2019 ESC\/EAS guidelines for the","year":"2019","unstructured":"2019 ESC\/EAS guidelines for the. management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205.","journal-title":"Atherosclerosis"},{"key":"6204_CR12","doi-asserted-by":"crossref","unstructured":"Kr\u00e4henb\u00fchl S, Pavik-Mezzour I, von Eckardstein A. Unmet Needs in LDL-C Lowering: When Statins Won\u2019t Do! Drugs. 2016;76(12):1175\u201390.","DOI":"10.1007\/s40265-016-0613-0"},{"key":"6204_CR13","doi-asserted-by":"crossref","unstructured":"Grejtakova D, Boronova I, Bernasovska J, Bellosta S. PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes. Cardiovasc Drugs Ther. 2025;39(6):1439\u201351.","DOI":"10.1007\/s10557-024-07599-5"},{"issue":"1","key":"6204_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40256-015-0153-0","volume":"16","author":"GM Keating","year":"2016","unstructured":"Keating GM. Evolocumab: A Review in Hyperlipidemia. Am J Cardiovasc drugs: drugs devices other interventions. 2016;16(1):67\u201378.","journal-title":"Am J Cardiovasc drugs: drugs devices other interventions"},{"key":"6204_CR15","doi-asserted-by":"crossref","unstructured":"Boccara F, Caramelli B, Calmy A, Kumar P, L\u00f3pez JAG, Bray S, Cyrille M, Rosenson RS. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period. AIDS. 2022;36(5):675\u201382.","DOI":"10.1097\/QAD.0000000000003175"},{"key":"6204_CR16","doi-asserted-by":"publisher","first-page":"1384523","DOI":"10.3389\/fcvm.2024.1384523","volume":"11","author":"Y Ma","year":"2024","unstructured":"Ma Y, Fan H, Mi W, Ma J, Deng Y, Song Y, Li X. Proprotein convertase subtilisin\/kexin type 9 inhibitors protect against contrast-associated acute kidney injury in patients with atherosclerotic cardiovascular disease. Front Cardiovasc Med. 2024;11:1384523.","journal-title":"Front Cardiovasc Med"},{"issue":"06","key":"6204_CR17","first-page":"589","volume":"52","author":"Chinese Society of Cardiology CMA, Cardiology EBoCJo","year":"2024","unstructured":"Chinese Society of Cardiology CMA, Cardiology EBoCJo. Chinese Guideline for the Diagnosis and Management of Patients with Chronic Coronary Syndrome. Chin J Cardiol. 2024;52(06):589\u2013614.","journal-title":"Chin J Cardiol"},{"issue":"03","key":"6204_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCRESAHA.123.322596","volume":"38","author":"Z Wang","year":"2023","unstructured":"Wang Z, Liu J, Li J, Wu N, Lu G, Chen Z, Zhao D, Zhao S, Gao R, Guo Y, et al. Chinese Guidelines for Lipid Management (2023). Chin Circulation J. 2023;38(03):237\u201371.","journal-title":"Chin Circulation J"},{"issue":"20","key":"6204_CR19","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa0905368","volume":"361","author":"K Wheatley","year":"2009","unstructured":"Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361(20):1953\u201362.","journal-title":"N Engl J Med"},{"issue":"13","key":"6204_CR20","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIR.0b013e31828b82aa","volume":"127","author":"JL Anderson","year":"2013","unstructured":"Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF\/AHA guideline recommendations): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(13):1425\u201343.","journal-title":"Circulation"},{"issue":"1","key":"6204_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12882-025-04097-0","volume":"26","author":"MA Oktan","year":"2025","unstructured":"Oktan MA, Sarioglu O, Heybeli C, Ozdemir E, Atay I, Korucu B, Bildaci YD, Deger SM, Cavdar C, Celik A, et al. Predictors of kidney disease progression after renal artery stenting. BMC Nephrol. 2025;26(1):175.","journal-title":"BMC Nephrol"},{"key":"6204_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pcad.2021.03.003","volume":"65","author":"RD Safian","year":"2021","unstructured":"Safian RD. Renal artery stenosis. Prog Cardiovasc Dis. 2021;65:60\u201370.","journal-title":"Prog Cardiovasc Dis"},{"issue":"22","key":"6204_CR23","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA"},{"key":"6204_CR24","doi-asserted-by":"crossref","unstructured":"Demir M, Altay S. Development of Infection and Associated Factors in Patients With MINOCA: A Prospective Comparison With MI-CAD. Klimik Dergisi\/Klimik J. 2025;38(4):233\u201340.","DOI":"10.36519\/kd.2025.5353"},{"issue":"18","key":"6204_CR25","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"key":"6204_CR26","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.","DOI":"10.1161\/CIR.0000000000000625"},{"issue":"20","key":"6204_CR27","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, H\u00e4ner J, Gencer B, Crljenica C, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"6204_CR28","doi-asserted-by":"publisher","first-page":"112519","DOI":"10.1016\/j.biopha.2021.112519","volume":"146","author":"J Vicente-Valor","year":"2022","unstructured":"Vicente-Valor J, Garc\u00eda-Gonz\u00e1lez X, Ib\u00e1\u00f1ez-Garc\u00eda S, Dur\u00e1n-Garc\u00eda ME, de Lorenzo-Pinto A, Rodr\u00edguez-Gonz\u00e1lez C, M\u00e9ndez-Fern\u00e1ndez I, Percovich-Hualpa JC, Herranz-Alonso A, Sanjurjo-S\u00e1ez M. PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort. Biomed Pharmacother. 2022;146:112519.","journal-title":"Biomed Pharmacother"},{"key":"6204_CR29","doi-asserted-by":"crossref","unstructured":"Khatib R, Khan M, Barrowcliff A, Ikongo E, Burton C, Mansfield M, Hall A. Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors. Open heart. 2022;9(1):e001931.","DOI":"10.1136\/openhrt-2021-001931"},{"issue":"8","key":"6204_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s11883-022-01037-3","volume":"24","author":"L Ferhatbegovi\u0107","year":"2022","unstructured":"Ferhatbegovi\u0107 L, Mr\u0161i\u0107 D, Ku\u0161ljugi\u0107 S, Pojski\u0107 B. LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated? Curr Atheroscler Rep. 2022;24(8):635\u201342.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"6204_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/17843286.2019.1702823","volume":"75","author":"OS Descamps","year":"2020","unstructured":"Descamps OS, Verhaegen A, Demeure F, Langlois M, Rietzschel E, Mertens A, De Sutter J, Wallemacq C, Lancellotti P, De Backer G. Evolving concepts on the management of dyslipidaemia. Acta Clin Belg. 2020;75(1):80\u201390.","journal-title":"Acta Clin Belg"},{"issue":"9","key":"6204_CR32","first-page":"158989","volume":"1866","author":"V Schoop","year":"2021","unstructured":"Schoop V, Martello A, Eden ER, H\u00f6glinger D. Cellular cholesterol and how to find it. Biochim et Biophys Acta (BBA) - Mol Cell Biology Lipids. 2021;1866(9):158989.","journal-title":"Biochim et Biophys Acta (BBA) - Mol Cell Biology Lipids"},{"key":"6204_CR33","doi-asserted-by":"crossref","unstructured":"Wang HH, Garruti G, Liu M, Portincasa P, Wang DQ. Cholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances In reverse Cholesterol Transport. Ann Hepatol. 2017;16(Suppl. 1: s3-105.):s27\u2013s42.","DOI":"10.5604\/01.3001.0010.5495"},{"issue":"Suppl 2","key":"6204_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.arteri.2021.02.007","volume":"33","author":"T Padro","year":"2021","unstructured":"Padro T, Mu\u00f1oz-Garcia N, Badimon L. The role of triglycerides in the origin and progression of atherosclerosis. Clin e investigacion en arteriosclerosis: publicacion oficial de la Sociedad Esp de Arterioscler. 2021;33(Suppl 2):20\u20138.","journal-title":"Clin e investigacion en arteriosclerosis: publicacion oficial de la Sociedad Esp de Arterioscler"},{"issue":"1","key":"6204_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","volume":"90","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41\u201352.","journal-title":"Kidney Int"},{"issue":"3","key":"6204_CR36","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3346\/jkms.2005.20.3.502","volume":"20","author":"JR Park","year":"2005","unstructured":"Park JR, Jung TS, Jung JH, Lee GW, Kim MA, Park KJ, Kim DR, Chang SH, Chung SI, Hahm JR. A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas. J Korean Med Sci. 2005;20(3):502\u20135.","journal-title":"J Korean Med Sci"},{"issue":"6","key":"6204_CR37","first-page":"347","volume":"102","author":"RC Oh","year":"2020","unstructured":"Oh RC, Trivette ET, Westerfield KL. Management of Hypertriglyceridemia: Common Questions and Answers. Am Family Phys. 2020;102(6):347\u201354.","journal-title":"Am Family Phys"},{"issue":"12","key":"6204_CR38","doi-asserted-by":"publisher","first-page":"e033654","DOI":"10.1161\/JAHA.123.033654","volume":"13","author":"AS Volgman","year":"2024","unstructured":"Volgman AS, Koschinsky ML, Mehta A, Rosenson RS. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk. J Am Heart Association. 2024;13(12):e033654.","journal-title":"J Am Heart Association"},{"key":"6204_CR39","doi-asserted-by":"crossref","unstructured":"Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023;20(18):6721.","DOI":"10.3390\/ijerph20186721"},{"issue":"1","key":"6204_CR40","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48\u201360.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"6204_CR41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, \u010ce\u0161ka R, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483\u201392.","journal-title":"Circulation"},{"issue":"24","key":"6204_CR42","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts P, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275\u201384.","journal-title":"Eur Heart J"},{"issue":"10155","key":"6204_CR43","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet (London England). 2018;392(10155):1311\u201320.","journal-title":"Lancet (London England)"},{"issue":"1","key":"6204_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/eurheartj\/ehp455","volume":"31","author":"NWCJ van de Donk","year":"2009","unstructured":"van de Donk NWCJ, Kooij N, Visseren FLJ. Acute and chronic renal artery stenosis. Eur Heart J. 2009;31(1):14\u201314.","journal-title":"Eur Heart J"},{"issue":"2","key":"6204_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajh\/hpx154","volume":"31","author":"SM Herrmann","year":"2018","unstructured":"Herrmann SM, Textor SC. Current Concepts in the Treatment of Renovascular Hypertension. Am J Hypertens. 2018;31(2):139\u201349.","journal-title":"Am J Hypertens"},{"issue":"3","key":"6204_CR46","first-page":"999","volume":"48","author":"S Pi","year":"2023","unstructured":"Pi S, Li Y, Lin C, Li G, Wen H, Peng H, Wang J. Arterial spin labeling and diffusion-weighted MR imaging: quantitative assessment of renal pathological injury in chronic kidney disease. Abdom Radiol (New York). 2023;48(3):999\u20131010.","journal-title":"Abdom Radiol (New York)"},{"key":"6204_CR47","doi-asserted-by":"crossref","unstructured":"Biccir\u00e8 FG, Gatto L, La Porta Y, Pignatelli P, Prati F, Pastori D. Effects of Lipid Lowering Therapies on Vulnerable Plaque Features: An Updated Narrative Review of the Literature. J Cardiovasc Dev disease. 2023;10(6):260.","DOI":"10.3390\/jcdd10060260"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06204-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:03:11Z","timestamp":1790164991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06204-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6204"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06204-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all the enrolled participants. This study was carried out in accordance with the Declaration of Helsinki, after approval by The First Affiliated Hospital of Harbin Medical University (2025447).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study has never been published before.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"825"}}